A Phase II, Open Label, Single Arm Study To Assess The Efficacy Of Intratumoral Tigilanol Tiglate In Various Head And Neck Solid Malignancies
Latest Information Update: 14 May 2025
At a glance
- Drugs Tigilanol tiglate (Primary)
- Indications Carcinoma; Head and neck cancer; Laryngeal cancer; Salivary gland cancer; Solid tumours; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors QBiotics
Most Recent Events
- 07 May 2025 Planned number of patients changed from 37 to 20.
- 16 Aug 2023 According to a QBiotics Group Limited media release, QBiotics decided to end phase I/II trial (QB46C-H03) on the basis it had sufficient safety information to inform the Company's subsequent Human Clinical Phase II efficacy trial in head and neck cancer which is now open at multiple sites in Australia and the UK.
- 08 Jun 2023 According to a QBiotics Group Limited media release, data from this study will be presented at BIO International Convention through 5-8 June in Boston.